SEGMENT INFORMATION - Company`s Segment, Including Segment Expenses, and a Reconciliation to Net Income (loss) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total revenues		$ 1,901,979	$ 1,243,336	$ 933,013
Segment Expenses and Other Segment Items
Cost of sales (excluding amortization of in-licensed rights)		319,099	150,343	139,989
Selling, general and administrative- other (excluding non-cash items)		557,872	481,871	451,421
Interest expense		(18,391)	(22,010)	(53,248)
Loss on debt extinguishment		0	(387,329)	(125,441)
Net income (loss)		235,239	(535,977)	(703,488)
Reconciliation of profit or loss
Adjustments and reconciling items		0	0	0
Net Income (Loss)		235,239	(535,977)	(703,488)
Operating Segments Member
Segment Reporting Information [Line Items]
Total revenues		1,901,979	1,243,336	933,013
Segment Expenses and Other Segment Items
Cost of sales (excluding amortization of in-licensed rights)		319,099	150,343	139,989
Compensation and other personnel expenses		335,830	319,080	256,382
Manufacturing expenses		329,011	345,826	466,111
Clinical trial expenses		163,565	187,289	135,838
Facility- and technology-related expenses (excluding depreciation and amortization)		106,281	88,559	71,700
Research and development- other (excluding non-cash items)	[1]	108,597	118,727	117,171
Selling, general and administrative- other (excluding non-cash items)	[2]	226,598	181,310	124,948
Roche Collaboration Reimbursement		(127,107)	(106,885)	(117,807)
Other segment items	[3]	(30,449)	(49,129)	(11,014)
Interest expense		18,391	22,010	53,248
Interest income		(30,635)	(36,257)	(16,488)
Income tax expense		25,535	15,879	13,525
Depreciation and amortization expense		37,724	44,397	41,864
Stock-based compensation expense		184,300	182,514	233,018
Gain from sale of Priority Review Voucher		0	(102,000)	0
Impairment of strategic investments		0	30,321	2,575
Loss on debt extinguishment		0	387,329	125,441
Net income (loss)		235,239	(535,977)	(703,488)
Reconciliation of profit or loss
Net Income (Loss)		$ 235,239	$ (535,977)	$ (703,488)

[1] (a) Research and development-other includes professional services, up-front, milestone, and other expenses, pre-clinical expenses and research and other expenses.

[2] (b) Selling, general and administrative-other includes professional services and other expenses.

[3] (c) Other segment items included in segment net income (loss) include accretion of investment discount, net, change in fair value of derivatives and other, net, as well as the items separately presented and not defined as significant expenses below.